Document is current

Article History

First Online: 8 April 2019

Competing interests

: The University of Michigan has been issued a patent on <i>ETS</i> gene fusions in prostate cancer on which S.A.T. is a coinventor. The diagnostic field of use has been licensed to Hologic (which acquired Gen-Probe), which has sublicensed rights to Roche (which owns Ventana Medical Systems). S.A.T. has received travel support from, and had a sponsored research agreement with, Compendia Bioscience (which was acquired by Life Technologies, which was acquired by ThermoFisher Scientific). S.A.T. has sponsored research agreements with Astellas and GenomeDx. S.A.T. has served as a consultant for and received honoraria from Roche, Ventana Medical Systems, Almac Diagnostics, Janssen, AbbVie, Sanofi and Astellas (which acquired Medivation). S.A.T. is a cofounder of, consultant for and the Laboratory Director of Strata Oncology. P.N.M. and M.T. are co-founders of XING Technologies, which has licensed intellectual property from the University of Queensland, Australia. P.N.M. is a shareholder of XING Technologies. P.N.M. has served as a consultant, advisory board member and lecturer for and received honoraria, travel support and grant support from Astellas, Bristol-Myers Squibb, Ipsen, Janssen, Medivation, Merck, Novartis, Pfizer and Genentech (a subsidiary of Roche). K.M.K. declares no competing interests.